KR20240110642A - 신경학적 장애의 치료 방법 - Google Patents

신경학적 장애의 치료 방법 Download PDF

Info

Publication number
KR20240110642A
KR20240110642A KR1020247020828A KR20247020828A KR20240110642A KR 20240110642 A KR20240110642 A KR 20240110642A KR 1020247020828 A KR1020247020828 A KR 1020247020828A KR 20247020828 A KR20247020828 A KR 20247020828A KR 20240110642 A KR20240110642 A KR 20240110642A
Authority
KR
South Korea
Prior art keywords
compound
fesoterodine
administered
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020828A
Other languages
English (en)
Korean (ko)
Inventor
제임스 릴리에
마이클 우드
Original Assignee
맵라이트 세라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 맵라이트 세라퓨틱스, 인크. filed Critical 맵라이트 세라퓨틱스, 인크.
Publication of KR20240110642A publication Critical patent/KR20240110642A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247020828A 2021-11-24 2022-11-23 신경학적 장애의 치료 방법 Pending KR20240110642A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163283140P 2021-11-24 2021-11-24
US63/283,140 2021-11-24
US202263416745P 2022-10-17 2022-10-17
US63/416,745 2022-10-17
PCT/US2022/080429 WO2023097276A1 (en) 2021-11-24 2022-11-23 Methods of treating neurological disorders

Publications (1)

Publication Number Publication Date
KR20240110642A true KR20240110642A (ko) 2024-07-15

Family

ID=86540399

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020828A Pending KR20240110642A (ko) 2021-11-24 2022-11-23 신경학적 장애의 치료 방법

Country Status (9)

Country Link
US (1) US20250032460A1 (https=)
EP (1) EP4436564A4 (https=)
JP (1) JP2024541770A (https=)
KR (1) KR20240110642A (https=)
AU (1) AU2022396530A1 (https=)
CA (1) CA3239067A1 (https=)
IL (1) IL313067A (https=)
MX (1) MX2024006371A (https=)
WO (1) WO2023097276A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3061821T (pt) * 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
US8853219B2 (en) * 2010-01-11 2014-10-07 Neurosolis, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination

Also Published As

Publication number Publication date
CA3239067A1 (en) 2023-06-01
US20250032460A1 (en) 2025-01-30
JP2024541770A (ja) 2024-11-12
EP4436564A4 (en) 2025-10-22
EP4436564A1 (en) 2024-10-02
IL313067A (en) 2024-07-01
MX2024006371A (es) 2024-07-15
AU2022396530A1 (en) 2024-06-13
WO2023097276A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US9913836B2 (en) Anticholinergic neuroprotective composition and methods
TWI684450B (zh) 猝倒症之治療
EP3630102B1 (en) Formulations for treatment of post-traumatic stress disorder
JP2003515564A (ja) Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
US20140088145A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
MX2012011395A (es) Metodos de mejoramiento de la calidad del sueño.
EP4275750A2 (en) Treatment of alzheimer's disease in a particular patient population
AU2017341825A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
US11000519B2 (en) Pridopidine for treating drug induced dyskinesias
WO2011028794A2 (en) Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
RU2432161C1 (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств
JPWO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
JP4980226B2 (ja) 眼科用組成物及びその使用方法
KR20240110642A (ko) 신경학적 장애의 치료 방법
US9066949B2 (en) Compositions and methods for the treatment of catatonia
US7915262B2 (en) Combination preparations comprising SLV308 and a dopamine agonist
CN118510500A (zh) 治疗神经系统障碍的方法
CN1300217A (zh) 瑞波西汀与吲哚洛尔的新的药物组合
KR20090031908A (ko) Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
US12036213B2 (en) Pridopidine for treating drug induced dyskinesias
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000